The 7 Most Undervalued Blue-Chip Stocks to Buy Now: June 2023

In This Article:

Looking for undervalued blue-chip stocks to buy? This is a great time to be doing so. The stock market as a whole is enjoying a strong rally. And yet, there are still plenty of blue-chip stocks with high potential today. Investors might think that they have to give up the possibility of large capital gains to invest in safer conservative companies. But these seven best-value blue-chip stocks to buy offer upside at a good starting price. Morningstar agrees, with all seven of these picks being among their 4- or 5-star stocks today, suggesting they are on sale now.

Blue-Chip Stocks to Buy: Danaher (DHR)

a bull next to a stack of blue gambling chips to represent blue-chip stocks, blue-chip stocks to buy
a bull next to a stack of blue gambling chips to represent blue-chip stocks, blue-chip stocks to buy

Source: Shutterstock

One of the top blue-chip stocks to buy is Danaher (NYSE:DHR), a healthcare company focused on laboratory tools and services.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

That is a recent development, however, as Danaher began as an industrial conglomerate with a wide array of products. Over the years, management has been a whirlwind of mergers and acquisitions, deftly adding and divesting operations. It’s been so successful, in fact, that a $10,000 investment in Danaher shares in June 1993 would now be worth a stunning $1.73 million. Danaher hasn’t gotten complacent with its success. In fact, the firm is rapidly reinventing itself once again. It has already divested almost all of its slower-moving businesses, and the spin-off for its water business will conclude later this year.

At that point, Danaher will be solely focused on healthcare, primarily on the tools and equipment needed for drug discovery. Analysts expect bioprocessing, in particular, to be a huge growth market over the next decade, and DHR stock will be a big beneficiary. Sales sold off as COVID-related sales have faded, however, that makes for a great entry point today.

Becton, Dickinson (BDX)

A close-up shot of a blue casino chip on red carpet.
A close-up shot of a blue casino chip on red carpet.

Source: Shutterstock

Becton, Dickinson (NYSE:BDX) is a leading medical devices company focused on surgical implements. Its core business is in making syringes, needles, infusion pumps, medication dispensers, and so on.

These basic goods may seem like commodity products, but Becton, Dickinson has a major scale advantage due to its large size and durable relationships with hospitals, insurers, and other key players. And, like Danaher, it will naturally see revenues rise as the population ages and needs more surgeries and medical procedures.

In recent years, Becton, Dickinson saw a surge in revenues related to temporary demand from COVID-19-related products. That has faded recently, and BDX stock has underperformed amid the slowdown. However, the company has reinvested profits into faster-growing device lines which should power growth in future years. Morningstar’s Alex Morozov sees shares as 16% undervalued today.